# Medical Cannabis Beyond Pain: PM&R Review on Spasticity, Seizures, Sleep & Nausea > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/medical-cannabis-non-pain-indications-pmr-review/ > **Published:** 2026-07-30T10:16:20-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:48:12-04:00 > **Clinical Summary:** Explore medical cannabis non-pain indications with a PM&R review focusing on spasticity, seizures, sleep, and chemotherapy-induced nausea benefits and risks. --- CED Clinical Relevance #80 Clinical Evidence Update A PM&R-focused narrative review synthesizes human evidence on [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) for non-pain indications, but as a narrative rather than systematic review it warrants a measured, condition-specific reading. Clinical Insight | CED Clinic This review matters because it asks a question pain-focused cannabis coverage usually skips: does cannabis help patients regain function, not just feel less symptomatic. Physical Medicine and Rehabilitation measures success in mobility, independence, and quality of life, and the authors are candid that cannabis evidence for those specific outcomes remains thin even where symptom-level benefits, spasticity, seizures, nausea, appetite, are better supported. For a family medicine and cannabis-medicine practice, that distinction is the clinical takeaway: a treatment can ease a symptom and still fall short of the rehabilitation goal that brought the patient into care, which is exactly the kind of honest gap analysis this specialty needs. [Medical Cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/)PM&RSpasticity[Endocannabinoid System](https://cedclinic.com/endocannabinoid-system-fear-extinction/)Rehabilitation Audience Physicians, physical medicine and rehabilitation clinicians, patients in rehabilitation care, and caregivers evaluating medical cannabis for non-pain symptoms Primary Topic medical cannabis for non-pain indications in physical medicine and rehabilitation, including spasticity, seizures, sleep, and chemotherapy-induced nausea Source [Read the full source](https://pubmed.ncbi.nlm.nih.gov/42524265/) ## Medical Cannabis Beyond Pain: What a New PM&R Review Says About Spasticity, Seizures, Sleep, and Nausea A new PM&R-focused narrative review synthesizes evidence on medical cannabis for non-pain conditions, including spasticity, seizure disorders, sleep disturbance, and chemotherapy-induced nausea and vomiting. The review reports modest, patient-reported symptom benefits but is candid that evidence for functional-outcome improvement, the core goal of rehabilitation medicine, remains limited. What This Study Teaches Us The review suggests cannabinoids, acting through CB1- and CB2-receptor-mediated pathways in the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/), may produce modest, patient-reported symptom benefits beyond pain, including reduced spasticity in multiple sclerosis, fewer seizures in treatment-resistant pediatric epileptic syndromes, antiemetic effects in refractory chemotherapy-induced nausea and vomiting, and [appetite stimulation](https://cedclinic.com/dronabinol-hiv-wasting-syndrome-appetite-weight-gain/) in cachectic states. It also shows why symptom-level improvement is not the same as the functional-recovery outcomes that define rehabilitation medicine. Why This Matters PM&R clinicians manage patients for whom functional independence, not just symptom relief, is the treatment goal. As more patients ask about medical cannabis for non-pain symptoms, clinicians need a clear-eyed synthesis of what the literature actually supports, where it stops short of functional outcomes, and what rehabilitation-specific risks, including sedation and fall risk, require monitoring. Study Snapshot Study Type PM&R-focused narrative review of the medical cannabis literature (not a systematic review or meta-analysis) Clinical Focus Non-pain indications of medical cannabis in physical medicine and rehabilitation Conditions Reviewed Spasticity, neurologic and seizure disorders, sleep disturbances, and chemotherapy-induced nausea and vomiting (CINV) Mechanism Discussed Endocannabinoid system signaling through CB1- and CB2-receptor-mediated pathways affecting neuromodulation, inflammation, and homeostasis Reported Benefits Patient-reported spasticity improvement in multiple sclerosis, seizure reduction in treatment-resistant pediatric epileptic syndromes, antiemetic effects in refractory CINV, and [appetite stimulation](https://cedclinic.com/dronabinol-hiv-wasting-syndrome-appetite-weight-gain/) in cachectic states Sleep Findings Subjective sleep quality improvements reported, but objective sleep architecture changes were inconsistent across studies Functional Outcome Evidence The authors describe limited evidence for meaningful improvement in functional outcomes and quality of life, the core PM&R endpoints Rehabilitation Risks Noted Dose-dependent [cognitive impairment](https://cedclinic.com/acute-effects-partial-cb1-receptor-agonists-cognition/), sedation, impaired motor learning, and increased fall risk Evidence Gaps Lack of standardized dosing, variable THC:CBD formulations, inconsistent product labeling, and few high-quality randomized controlled trials measuring long-term functional outcomes Regulatory Context Discrepancies between federal and state cannabis law described as a continued barrier to clinical implementation and research Journal Archives of Internal Medicine Research Published July 2026 PMID 42524265 DOI 10.26502/aimr.0246 Clinical Bottom Line A PM&R-focused narrative review finds modest, patient-reported symptom benefits for spasticity, seizures, chemotherapy-induced nausea, and appetite, but concludes that evidence for functional outcome improvement remains limited and that cannabis carries rehabilitation-specific risks that require careful patient selection and monitoring. What the Review Covers This PM&R-centered narrative review synthesizes evidence on medical cannabis for non-pain indications: spasticity, neurologic and seizure disorders, sleep disturbances, and chemotherapy-induced nausea and vomiting. The authors frame their synthesis around the endocannabinoid system itself, describing CB1- and CB2-receptor-mediated pathways that influence neuromodulation, inflammation, and homeostasis as the mechanistic basis for these non-pain effects. Where Cannabinoids Showed Reported Benefit Across the conditions reviewed, the authors describe modest benefits in symptom reduction: improved patient-reported spasticity in multiple sclerosis, significant seizure reduction in treatment-resistant pediatric epileptic syndromes, antiemetic effects in refractory CINV, and appetite stimulation in cachectic states. Sleep quality improvements were also reported, though subjectively; objective changes in sleep architecture were inconsistent across the studies the review cites. Why Symptom Relief Is Not the Same as Functional Recovery The review is explicit that there remains limited evidence supporting meaningful improvements in functional outcomes and quality of life, the outcomes that define success in rehabilitation medicine. That is the central tension the authors highlight: a treatment can reduce a symptom score for spasticity or nausea without yet being shown to restore function or independence. Rehabilitation-Specific Risks The authors note that [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) may negatively impact rehabilitation through dose-dependent [cognitive impairment](https://cedclinic.com/acute-effects-partial-cb1-receptor-agonists-cognition/), sedation, impaired motor learning, and increased fall risk. These are not generic cannabis warnings; they are risks specifically relevant to a patient population working on balance, coordination, and cognitive tasks during active rehabilitation. Evidence and Regulatory Gaps Significant challenges persist, including a lack of standardized dosing, variability in formulations and THC:CBD ratios, inconsistent product labeling, and limited high-quality randomized controlled trials assessing long-term functional outcomes. Regulatory barriers, including discrepancies between federal and state cannabis law, further complicate clinical implementation and research, according to the review. How Strong Is This Evidence? This is a narrative review, not a systematic review or meta-analysis, so it does not apply a structured search protocol, risk-of-bias assessment, or pooled statistical analysis. Its value lies in synthesizing existing human evidence, including trials and clinical literature on spasticity, seizure disorders, CINV, and appetite, through a PM&R-specific clinical lens rather than in generating new data. Where This Paper Deserves Skepticism Because this is a narrative rather than systematic review, the selection of studies and the emphasis given to each finding depend on the authors’ judgment rather than a prespecified, reproducible search and inclusion protocol. Readers should treat qualitative language describing benefits, such as modest or significant, cautiously until the underlying primary studies are reviewed individually. What This Paper Does Not Show The review does not establish that medical cannabis improves functional independence, mobility, activities of daily living, or overall quality of life, the outcomes that matter most in rehabilitation medicine. It also does not provide standardized dosing guidance, compare specific formulations head-to-head, or resolve the discrepancy between federal and state cannabis law. How This Fits With the Broader Clinical Conversation This review sits alongside other CED Clinic coverage of cannabis-based medicines for multiple sclerosis spasticity and epilepsy, both of which show a similar pattern: real, replicated symptom-level signals paired with limited evidence for the broader functional or quality-of-life outcomes that matter most to patients. The rehabilitation-specific risks described here, sedation, cognitive impairment, and fall risk, are a reminder that a therapy can be symptom-positive and still complicate a specific clinical goal, in this case safe functional recovery, if it is not monitored and dosed carefully. Dr. Caplan’s Take *I welcome a PM&R-specific synthesis like this because rehabilitation medicine asks a different question than pain medicine alone: does a treatment help a patient regain function, not just feel less symptomatic. This review is honest that the evidence for that specific goal is still thin.* *My practical takeaway for rehabilitation-involved patients is that cannabis can be a reasonable part of a symptom-management conversation, spasticity, sleep, nausea, appetite, but it needs to be dosed and monitored with the same attention to sedation, cognitive effects, and fall risk that we would give any centrally acting medication in a patient working toward functional recovery.* What a Careful Reader Should Take Away A careful reader should take from this review a modest, condition-specific symptom signal for spasticity, seizures, CINV, and appetite, alongside a clear reminder that functional-outcome evidence, standardized dosing, and rehabilitation-specific safety data are still missing. Evidence Interpretation Guide ## How to Interpret This PM&R Review of Medical Cannabis Beyond Pain Without Overstating It A useful evidence report should let the signal breathe without inflating it. The right question is not whether the review is positive or negative, but what kind of decision it can responsibly support. ### A Four-Step Reading Frame **Evidence type**Start by identifying that this is a narrative review, not a randomized trial, systematic review, or meta-analysis, which changes how much weight its conclusions should carry. **Population**Ask whether the studies cited address the population and setting relevant to your question, since the review spans several different non-pain conditions rather than one uniform patient group. **Outcome meaning**Look at whether the reported outcome is a symptom measure, such as spasticity or seizure frequency, or a functional measure, such as independence or quality of life, since the review shows these move differently. **Safety and uncertainty**Read the rehabilitation-specific risks, cognitive impairment, sedation, and fall risk, as part of the clinical picture rather than an afterthought. The Research Question What does the current evidence suggest about medical cannabis for non-pain indications in physical medicine and rehabilitation? The Patient Question Does this mean I should use cannabis for my rehabilitation-related symptoms? The Bottom Line The evidence can inform a careful conversation with your rehabilitation team, but it does not replace individualized clinical care or establish cannabis as a routine rehabilitation therapy. CED Perspective Lens ## The Same Study Can Mean Different Things Depending on the Question Being Asked Scientific papers rarely answer a single question. Patients, clinicians, researchers, policymakers, and critics often read the same data differently. The perspectives below explore how this study looks through several evidence-based lenses. Lens Overview This review can be read through several lenses. The most useful readings keep medical cannabis for non-pain indications in physical medicine and rehabilitation clinically relevant without treating a narrative synthesis as more settled than it is. #### A Reasonable Add-On to Discuss, Not a Rehabilitation Shortcut If you are in physical or occupational therapy and considering medical cannabis for spasticity, sleep, nausea, or appetite, this review supports raising it as one option among several, not a stand-alone fix. The same review that describes symptom benefit also describes sedation, cognitive slowing, and fall risk, effects that matter directly to your safety during therapy sessions and daily function. Lens takeaway Bring [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) to your rehabilitation team before you start, so dosing and timing can be planned around your therapy schedule and fall risk. #### A Useful Framework for a Common Question PM&R clinicians are increasingly asked about cannabis for non-pain symptoms, and this review offers a structured, condition-by-condition summary rather than a single blanket answer. Because it is a narrative review, it is best used to frame the conversation and identify which primary studies to read in full before making patient-specific recommendations. Lens takeaway Use the review as a starting map of the literature, then verify the primary studies most relevant to your patient’s condition. #### Narrative Reviews Reflect Author Judgment Without a prespecified search protocol or risk-of-bias grading, a narrative review can emphasize studies that fit its framing more than a systematic review would. Terms like modest benefit and significant seizure reduction should be checked against the specific primary trials before being treated as settled findings. Lens takeaway Treat this as a well-organized starting point for further reading, not a final verdict on efficacy. #### Symptom Scores Are Not Functional Outcomes The review itself acknowledges that evidence for meaningful improvement in functional outcomes and quality of life remains limited, even where symptom-level benefits are reported. A PM&R practice is built around functional recovery, so a therapy that helps a symptom score without helping function has not yet answered the question that matters most to this specialty. Lens takeaway Ask what outcome was actually measured, symptom relief or functional gain, before drawing conclusions. #### Consistent With, Not Beyond, Prior Cannabis Evidence The pattern described here, real symptom-level signals for spasticity, seizures, and nausea alongside thin functional-outcome data, matches what CED Clinic has covered in prior reporting on nabiximols for multiple sclerosis and CBD for epilepsy. This review adds a PM&R-specific lens to that pattern rather than new primary data. Lens takeaway This is a synthesis and reframing of existing evidence, not a new clinical trial result. #### Monitoring Has to Match the Rehabilitation Goal The review flags dose-dependent cognitive impairment, sedation, impaired motor learning, and increased fall risk, all directly relevant to a rehabilitation program’s safety. Timing cannabis use around therapy sessions, starting at low doses, and tracking cognitive and balance changes are reasonable precautions given these specific findings. Lens takeaway Fall risk and motor learning monitoring deserve as much attention as symptom tracking in this population. #### PM&R-Specific Trials Are the Missing Piece The authors call directly for PM&R-specific research using rehabilitation-relevant outcomes, such as objective measures of functional independence and quality of life, rather than symptom scores alone. Standardized dosing, consistent THC:CBD formulations, and long-term randomized data are named as the gaps that would most improve clinical confidence. Lens takeaway The next useful study is one that measures function, not just symptoms. #### Federal-State Conflict Still Shapes Clinical Practice The review notes that discrepancies between federal and state cannabis law complicate clinical implementation and research, a barrier that affects PM&R practices as much as any other specialty. Until that regulatory conflict resolves, clinicians will keep working with an evidence base that is harder to standardize and study than a Schedule III or unscheduled medication would allow. Lens takeaway Policy uncertainty is not just a legal footnote; it is part of why the evidence base described here remains incomplete. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=Medical+Cannabis+Beyond+Pain%3A+What+a+New+PM%26R+Review+Says+About+Spasticity%2C+Seizures%2C+Sleep%2C+and+Nausea&url=https%3A%2F%2Fcedclinic.com%2Fmedical-cannabis-beyond-pain-pmr-review%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fmedical-cannabis-beyond-pain-pmr-review%2F) [BlueSky](https://bsky.app/intent/compose?text=Medical+Cannabis+Beyond+Pain%3A+What+a+New+PM%26R+Review+Says+About+Spasticity%2C+Seizures%2C+Sleep%2C+and+Nausea%20https%3A%2F%2Fcedclinic.com%2Fmedical-cannabis-beyond-pain-pmr-review%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Therapeutic Use of Medical Cannabis Beyond Pain Management in Physical Medicine and Rehabilitation.](https://pubmed.ncbi.nlm.nih.gov/42524265/) Related Reading at CED Clinic Continue exploring the evidence [Nabiximols for MS: What a New Meta-Analysis Shows Beyond Spasticity](https://cedclinic.com/nabiximols-multiple-sclerosis-beyond-spasticity-meta-analysis/) A pooled analysis of nabiximols in multiple sclerosis, directly relevant to the spasticity indication discussed in this PM&R review. [Read the MS spasticity meta-analysis](https://cedclinic.com/nabiximols-multiple-sclerosis-beyond-spasticity-meta-analysis/) [Purified CBD and Epilepsy: Insights on Nonseizure Outcomes from New Review](https://cedclinic.com/highly-purified-cannabidiol-epilepsy-nonseizure-outcomes/) A companion look at CBD for seizure disorders, one of the same non-pain indications covered in this PM&R synthesis. [Read the CBD epilepsy review](https://cedclinic.com/highly-purified-cannabidiol-epilepsy-nonseizure-outcomes/) [What 102 Systematic Reviews Say About Cannabis for Pain, IBD, and MS](https://cedclinic.com/systematic-review-cannabis-pain-evidence-2026/) Broader context on where cannabinoid evidence is strongest and weakest across conditions, useful for comparing against this review’s PM&R-specific gaps. [See the broader evidence map](https://cedclinic.com/systematic-review-cannabis-pain-evidence-2026/) ## Frequently Asked Questions Does this review prove that medical cannabis improves rehabilitation outcomes? No. It reports modest, symptom-level benefits for conditions like spasticity and seizures, but the authors describe evidence for functional outcome improvement as limited. What kind of study is this? It is a narrative review of the literature focused on physical medicine and rehabilitation, not a randomized controlled trial, systematic review, or meta-analysis. Which conditions did the review focus on? It focused on non-pain indications: spasticity, neurologic and seizure disorders, sleep disturbances, and chemotherapy-induced nausea and vomiting. How does cannabis affect these conditions, according to the review? The review describes cannabinoid activity through CB1- and CB2-receptor-mediated pathways in the endocannabinoid system, which influence neuromodulation, inflammation, and homeostasis. What risks does the review highlight for rehabilitation patients? It highlights dose-dependent cognitive impairment, sedation, impaired motor learning, and increased fall risk, all directly relevant to a rehabilitation program. Did the review find consistent sleep benefits? It found subjective improvements in sleep quality, but objective changes in sleep architecture were inconsistent across the studies reviewed. What is missing from the current evidence base? Standardized dosing, consistent THC:CBD formulations, consistent product labeling, and high-quality randomized controlled trials measuring long-term functional outcomes are all described as missing. Does state legalization resolve the regulatory barriers mentioned? No. The review notes that discrepancies between federal and state cannabis law continue to complicate clinical implementation and research regardless of state legal status. Should patients start using cannabis for rehabilitation-related symptoms based on this review alone? No. The review supports discussing cannabis as one option among several with a rehabilitation team, not starting it independently based on a literature synthesis. What would make this evidence more convincing? PM&R-specific trials that measure functional independence and quality of life directly, rather than symptom scores alone, would most improve confidence in a rehabilitation-specific role for medical cannabis.   ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).